Bioxytran (BIXT) Stock Price, News & Analysis

Company Overview

Bioxytran, Inc. is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release. These formulations are engineered to minimize oxidative stress and inflammation while enhancing tissue recovery. The company maintains a patent portfolio covering key geographies, including North America, Europe, and Asia, and is actively exploring collaborative partnerships to support development and potential global commercialization.

Originating from foundational work in synthetic oxygen therapeutics, Bioxytran has transitioned from early-stage research into a specialized biopharmaceutical developer. The management team brings together expertise in biotechnology R&D, regulatory strategy, and manufacturing scale-up. Bioxytran continues to pursue strategic alliances and funding initiatives to advance its mission of delivering innovative oxygen-based therapies that improve patient outcomes in critical therapeutic areas.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.06 to $0.09
• 52-Week Range: $0.06 to $0.23
• Volume: 2,761 shs
• Average Volume: 172,966 shs
• Market Capitalization: $6.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bioxytran Stock Analysis - MarketRank™

Bioxytran scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bioxytran.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioxytran is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioxytran is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Bioxytran have been sold short.

Short Interest Ratio / Days to Cover

Bioxytran has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bioxytran has recently decreased by 97.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioxytran does not currently pay a dividend.

Dividend Growth

Bioxytran does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Bioxytran have been sold short.

Short Interest Ratio / Days to Cover

Bioxytran has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bioxytran has recently decreased by 97.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Bioxytran has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bioxytran this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioxytran insiders have not sold or bought any company stock.

Percentage Held by Insiders

70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.

BIXT Stock Analysis - Frequently Asked Questions

How have BIXT shares performed this year?

Bioxytran's stock was trading at $0.0899 at the start of the year. Since then, BIXT shares have decreased by 21.0% and is now trading at $0.0710.

How were Bioxytran's earnings last quarter?

Bioxytran, Inc. (OTCMKTS:BIXT) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) EPS for the quarter.

How do I buy shares of Bioxytran?

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioxytran own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 10/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BIXT
• CIK: 1445815
• Web: www.bioxytraninc.com
• Phone: (617) 454-1199
• Fax: N/A
• Employees: 2
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,577.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -3.55

Miscellaneous

• Outstanding Shares: 88,990,000
• Free Float: 26,698,000
• Market Cap: $6.32 million
• Optionable: Not Optionable
• Beta: 1.35